key: cord-0832406-kkda12sz
authors: Zhang, Sun; Xu, Yuanda; Li, Jieying; Wu, Kang; Wang, Tao; Su, Xiaofen; Han, Qian; Xi, Yin; Gao, Yong; Wang, Hongbo; Hu, Yu; Liu, Chunli; Ran, Pixin; Zhang, Nuofu; Zhong, Nanshan
title: Symptomless multi-Variable apnea prediction index assesses adverse outcomes in patients with Corona Virus Disease 2019
date: 2020-09-04
journal: Sleep Med
DOI: 10.1016/j.sleep.2020.08.031
sha: 98472890ae5c996fba67aeaede28c9aca768eeae
doc_id: 832406
cord_uid: kkda12sz

PURPOSE: To explore the relationship between symptomless multi-Variable apnea prediction (sMVAP) index and adverse outcomes of patients with Corona Virus Disease 2019 (COVID-19). METHODS: According to the sMVAP quartiles, we divided all patients into four groups. The clinical electronic medical records, nursing records, laboratory findings, and radiological examinations for all patients with laboratory confirmed Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection were reviewed. Cox proportional hazard ratio (HR) models were used to determine the risk factors associated with in hospital death. RESULTS: A total of 97 patients were included in this study. The “Quartile 4” group 's ICU transfer rate was significantly higher than the “Quartile 1” group. Coronary heart disease, high d-dimer and sMVAP at admission were associated with increased odds of death. CONCLUSIONS: Using the sMVAP index for obstructive sleep apnea hypopnea syndrome (OSAHS) risk assessment, and then predicting the adverse outcomes of COVID-19 patients, is an effective method. Therefore, the use of sMVAP index for OSAHS screening for inpatients with COVID-19 should be vigorously promoted, and high-risk patients should be effectively managed.

The outbreak of COVID-19 has lasted for more than half a year and has been steadily spreading at the global level, World Health Organization (WHO) had called it pandemic. During the epidemic, due to cross-infection issues, PSG has not been widely used in patients with COVID-19, which makes the impact of OSAHS on patients with COVID-19 unknown. At the same time, due to the lack of sufficient attention to OSAHS, many patients were not collected for OSAHS-related clinical manifestations such as neck circumference, snoring, and daytime sleepiness, Therefore, it is difficult to use the J o u r n a l P r e -p r o o f STOP-Bang questionnaire [1] and NoSAS questionnaire [2] to perform OSAHS screening for COVID-19 patients. The sMVAP index has proved to be an effective tool for screening OSAHS [3] , including only parameters such as gender, age and body mass index (BMI). This study explored the relationship between sMVAP index and adverse outcomes of patients with COVID-19, trying to reveal the effect of OSAHS on COVID-19.

This single-center, retrospective, observational study was done at Wuhan Union Hospital (Wuhan, China). We retrospectively analyzed patients from Jan 29, 2020, to Mar 23, 2020, who had been diagnosed with COVID-19, according to WHO interim guidance [4] . Laboratory confirmation of SARS-CoV-2 infection was performed by the local health authority.

Medical University approved this study (IRB:202051). Written informed consent was waived due to the rapid emergence of this infectious disease.

We reviewed clinical electronic medical records, nursing records, laboratory findings, and radiological examinations for all patients with laboratory confirmed SARS-CoV-2 infection. The admission data of these patients were collected. J o u r n a l P r e -p r o o f

The primary outcome was the mortality from hospital admission to the cut off date. The cut-off date was set to the date of the last patient's outcome (death or discharge from hospital). In this study, the cut-off date was May, 2, 2020. Secondary outcome was the rate of any stay in ICU. Sepsis and septic shock were defined according to the 2016 Third International Consensus Definition for Sepsis and Septic Shock [5] . Secondary infection was diagnosed when patients showed clinical symptoms or signs of pneumonia or bacteremia and a positive culture of a new pathogen was obtained from lower respiratory tract specimens (qualified sputum, endotracheal aspirate, or bronchoalveolar lavage fluid) or blood samples after admission [5] . Acute kidney injury was diagnosed according to the KDIGO clinical practice guidelines [6] and acute respiratory distress syndrome (ARDS) was diagnosed according to the Berlin Definition [7] . The illness severity of COVID-19 was defined according to the Chinese management guideline for COVID-19 (version 7.0) [8] .

The purpose of this study is to explore the relationship between sMVAP and adverse outcomes in patients with COVID-19. There were, therefore, no formal hypotheses being implemented to drive the sample size calculation and we included the maximum number of patients who met the inclusion criteria.

The sMVAP index is calculated as: sMVAP = e X / (1 + e X ), where "e" is natural constant (Its value is about 2.718281828459) and X = −10.784 + 0.203 J o u r n a l P r e -p r o o f 7 × (BMI) + 0.043 × (Age) + 1.004 × (Gender: 0 = female, 1 = male) [3] . The sMVAP ranges from 0 to 1, with higher values indicating higher OSAHS risk.

To provide clinically-relevant interpretations, we based analyses on sMVAP quartiles (patients were divided into four groups). We expressed descriptive data as mean (SD) or median (IQR) for continuous variables and number (%) for categorical variables. We assessed differences between different groups using one-way ANOVA or kruskal-wallis H test depending on parametric or nonparametric data for continuous variables and Fisher's exact test for categorical variables. Cox proportional HR models were used to determine HRs and 95% CIs between individual factors on mortality. Previous studies have shown blood levels of d-dimer and history of coronary heart disease associated with adverse clinical outcomes in patients with COVID-19 [17, 18] . Some laboratory findings, including alanine aminotransferase (ALT), lactate dehydrogenase, high-sensitivity cardiac troponin I, and d-dimer, might be unavailable in emergency circumstances. Therefore, we chose d-dimer, coronary heart disease, and sMVAP index as the three variables for our multivariable Cox proportional HR models. Survival curves were developed using the Kaplan-Meier method with log-rank test. Time to events (death) were defined as the time from hospital admission to events. Since the P value of the log-rank test between the four groups was >0.05, we only performed survival analysis on the "Quartile 1" and "Quartile 4" group.

Tests were two-sided with significance set at α less than 0.05. The SPSS J o u r n a l P r e -p r o o f 24.0 software (IBM SPSS) was applied for all analyses.

A total of 97 patients were included in this study (figure 1 were treated with high-flow nasal cannula, three (3.1%) with extracorporeal membrane oxygenation (ECMO), eight (8.2%) patients were treated with continuous renal replacement therapy (CRRT). The proportion of patients in the "Quartile 4" group using invasive mechanical ventilation was significantly higher than that in the "Quartile 1" group. There was no significant difference in the proportion of non-invasive mechanical ventilation (NIMV) between groups.

There were 82 patients (84.5%) discharged before the cut-off date.

Although the mortality of the "Quartile 4" group is almost eight times that of the "Quartile 1" group, there was no significant difference in mortality between groups. The "Quartile 4" group 's ICU transfer rate was significantly higher than J o u r n a l P r e -p r o o f the "Quartile 1" group. The median time of hospital length of stay was 22 days (IQR 15-34.5) and there was no significant difference in that between groups.

The most common complications was secondary infection (10.3%), acute kidney failure (8.2%) and respiratory failure (8.2%) (table 2).

In univariable analysis, odds of in-hospital death was higher in "Quartile 4" group (table 3) . Old age, male sex, coronary heart disease, lactate dehydrogenase, high-sensitive cardiac troponin I, prothrombin time and d-dimer were also associated with death (table 3). In the multivariable Cox proportional HR models, we found that coronary heart disease, high d-dimer and sMVAP at admission were associated with increased odds of death (table   3) 

This retrospective cohort study identified the relationship between OSAHS risk and the mortality and ICU transfer rate in patients in Wuhan who were hospitalised with COVID-19. In particular, coronary heart disease, d-dimer levels greater than 0.5 μg/L, and higher sMVAP on admission were associated with higher odds of in-hospital death. Additionally, elevated ICU transfer rate and the incidence of complications were more commonly seen in higher J o u r n a l P r e -p r o o f sMVAP patients. To our knowledge, this is the first study to explore the association between sMVAP index and COVID-19.

During the COVID-19 pandemic, considering that SARS-CoV-2 was highly contagious, sleep monitoring for inpatients was inconvenient to carry out. A multi-center study from Europe pointed out that the number of polysomnography in Lab fell by more than 70% during the pandemic [9] . The Canadian Chest Association also recommends that patients should not be tested for sleep disordered breathing during the pandemic unless a clinician determines that a case is "extremely urgent" [10] . At the same time, despite the lack of clinical trials, based on the pathophysiology of OSAHS, some scholars believe that OSAHS could lead to increased risk of COVID-19 infection and severity [11] [12] [13] . We have noticed that there are two small sample studies showing that 21%-28.6% of critically ill COVID-19 patients were accompanied by OSAHS on admission [14, 15] . Although the above studies did not analyze the impact of OSAHS on the prognosis of critically ill COVID-19 patients, one of the studies pointed out that patients with coexisting conditions were at risk for severe disease and poor outcomes after ICU admission [14] , which indirectly reflects the negative impact of OSAHS on the progress of COVID-19. circumference. Therefore, we cannot use the above questionnaires to assess patients' OSAHS risk.

Previous studies reported that old age, male sex and obesity are independent risk factors for COVID-19 mortality [16] [17] [18] . Although the above indicators are also risk factors for OSAHS, it is relatively one-sided to use one or two alone to evaluate the risk of OSAHS. The sMVAP index proves to be a practical OSAHS screening tool [3] , including parameters such as age, gender, and BMI that only need to be extracted from the patient's electronic medical record. In this current study, the increased D-dimer and history of coronary heart disease were associated with poor prognosis, reflecting the direct effect of patients' coagulation function and cardiac dysfunction on mortality, consistent with previous reports [19, 20] .

This study has several limitations. First, due to the specificity of SARS-CoV-2, none of the patients underwent PSG test, so the efficacy of SMVAP index in screening OSAHS could not be evaluated. Secondly, since this study is a retrospective study, we cannot collect this information of sequential organ failure assessment (SOFA) score and acute physiology and chronic health evaluation II (APACHE II) score.

In conclusion, this study confirms that using the sMVAP index for OSAHS risk assessment, and then predicting the adverse outcomes of COVID-19 patients, is an effective method. Therefore, the use of sMVAP index for OSAHS screening for inpatients with COVID-19 should be vigorously promoted, and high-risk patients should be effectively managed.

We thank all patients and their families involved in the study. CRP, c-reactive protein; BNP, brain natriuretic peptide; a, compared with the "Quartile 2" group, P value of the "Quartile 1" was ≤ 0,05; b, compared with the "Quartile 3" group, P value of the "Quartile 1" was ≤ 0,05; c, compared with the "Quartile 4" group, P value of the "Quartile 1" was ≤ 0,05; d, compared with the "Quartile 2" group, P value of the "Quartile 3" was ≤ 0,05; e, compared with the "Quartile 2" group, P value of the "Quartile 4" was ≤ 0,05; f, compared with the "Quartile 3" group, P value of the "Quartile 4" was ≤ 0,05. , median (IQR) or n (%). sMVAP, symptomless multi-variable apnea prediction. ECMO, extracorporeal membrane oxygenation; CRRT, continuous renal replacement therapy; ICU, intensive care unit; DIC, disseminated intravascular coagulation; ARDS, acute respiratory distress syndrome; a, compared with the "Quartile 2" group, P value of the "Quartile 1" was ≤ 0,05; b, compared with the "Quartile 3" group, P value of the "Quartile 1" was ≤ 0,05; c, compared with the "Quartile 4" group, P value of the "Quartile 1" was ≤ 0,05. 

STOP questionnaire: a tool to screen patients for obstructive sleep apnea

The NoSAS score for screening of sleep-disordered breathing: a derivation and validation study

Symptomless Multi-Variable Apnea Prediction Index Assesses Obstructive Sleep Apnea Risk and Adverse Outcomes in Elective Surgery

Clinical management of COVID-19

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China

KDIGO clinical practice guidelines for acute kidney injury

Acute respiratory distress J o u r n a l P r e -p r o o f syndrome: the Berlin Definition

National Health Commission of the People's Republic of China. Chinese management guideline for COVID-19 (version 7.0)

Sleep apnoea management in Europe during the COVID-19 pandemic: data from the European Sleep Apnoea Database (ESADA

Key Highlights From the Canadian Thoracic Society's Position Statement on Optimizing the Management of Sleep Disordered Breathing During the COVID-19 Pandemic

Does obstructive sleep apnea lead to increased risk of COVID-19 infection and severity

COVID-19 and obstructive sleep apnea

Potential influences of obstructive sleep apnea and obesity on COVID-19 severity

Covid-19 in Critically Ill Patients in the Seattle Region -Case Series

Characteristics and Outcomes of 21

Critically Ill Patients With COVID-19 in Washington State

Clinical Characteristics, Associated Factors, and Predicting COVID-19 Mortality Risk: A Retrospective Study in Wuhan

Obesity a Risk Factor for Severe COVID-19 Infection: Multiple Potential Mechanisms

Obesity in patients younger than is a risk factor for Covid-19 hospital admission

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Prognostic significance of cardiac injury in COVID-19 patients with and without coronary artery disease